Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 8/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozenoxacin SCHEMBL29379004 | 0.91 | TOP2A (0.45) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| Ozenoxacin SCHEMBL1711829 | 0.91 | TOP2A (0.45) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| SCHEMBL5733083 | 0.90 | TOP2A (0.47) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| Ozenoxacin SCHEMBL2551666 | 0.90 | TOP2A (0.45) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| Ozenoxacin SCHEMBL2551660 | 0.90 | TOP2A (0.45) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| Ozenoxacin SCHEMBL2550848 | 0.90 | TOP2A (0.45) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| Ozenoxacin SCHEMBL2553345 | 0.90 | TOP2A (0.45) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| Ozenoxacin SCHEMBL2553340 | 0.90 | TOP2A (0.45) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| Ozenoxacin SCHEMBL2548603 | 0.89 | TOP2A (0.44) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| SCHEMBL5742552 | 0.89 | TOP2A (0.45) | TOP2ATOP2BKCNH2KDM4EGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022363-B2 | Pharmaceutical topical compositions | FERRER INTERNACIONAL, S.A. (ES) | 2018-07-17 | — | — | US | disclosed |
| US-20160243104-A1 | PHARMACEUTICAL TOPICAL COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2016-08-25 | — | — | US | disclosed |
| US-9399014-B2 | Pharmaceutical topical compositions | FERRER INTERNACIONAL, S.A. (ES) | 2016-07-26 | — | — | US | disclosed |
| US-20160030338-A1 | Pharmaceutical Topical Compositions | FERRER INT (ES) | 2016-02-04 | — | — | US | disclosed |
| US-9180200-B2 | Pharmaceutical topical compositions | FERRER INTERNATIONAL, S.A. (ES) | 2015-11-10 | — | — | US | disclosed |
| US-20140187578-A1 | Pharmaceutical Topical Compositions | FERRER INTERNACIONAL, S.A. (ES) | 2014-07-03 | — | — | US | disclosed |
| US-20110263646-A1 | PHARMACEUTICAL TOPICAL COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2011-10-27 | — | — | US | disclosed |
| EP-1070713-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-6335447-B1 | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| EP-1070713-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022363-B2 | Pharmaceutical topical compositions | CYP51A1, CUTA, LSS | TOP2A 31/4885TOP2B 49/4885KCNH2 1254/4885 |
| US-20140187578-A1 | Pharmaceutical Topical Compositions | CYP51A1, CUTA, LSS | TOP2A 31/4885TOP2B 49/4885KCNH2 1254/4885 |
| US-20110263646-A1 | PHARMACEUTICAL TOPICAL COMPOSITIONS | CYP51A1, CUTA, LSS | TOP2A 31/4885TOP2B 49/4885KCNH2 1254/4885 |
| US-20160243104-A1 | PHARMACEUTICAL TOPICAL COMPOSITIONS | CYP51A1, CUTA, LSS | TOP2A 31/4885TOP2B 49/4885KCNH2 1254/4885 |
| US-20160030338-A1 | Pharmaceutical Topical Compositions | CYP51A1, CUTA, LSS | TOP2A 31/4885TOP2B 49/4885KCNH2 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.